History

Corporate Milestone
2016
Feb
JW Therapeutics founded in Shanghai
Jul
GMP cell therapy manufacturing infrastructure first put into use
2017
Jul
Introduced world-class CAR-T technology platform and completed technology development
2018
May
Completed series A financing totaling over USD100 million
Sep
JW Therapeutics (Suzhou) Co., Ltd. founded
Nov
Started world-leading commercial scale cell therapy manufacturing project
Dec
JW Therapeutics R&D center opened
2019
Feb
Recognized as a “Foreign-invested R&D center” by Shanghai Municipal People’s Government
Dec
Completed cell therapy commercial- scale manufacturing infrastructure in Suzhou
Dec
GMP quality management lab put into use
2020
May
Completed USD100 million series B financing
Jun
Acquired Syracuse Biopharma
Jun
Suzhou site obtained drug manufacturing license
Nov
Listed on the main board of the Hong Kong Exchanges and Clearing Limited, stock code 2126.HK
2021
Sep
Became the market authorization holder (MAH) for cell therapy product, and entered commercial stage
2022
Jun
JW Therapeutics’ cell immunotherapy drugs have successfully benefited 234 Chinese patients
Product Milestone
2017
Dec
Relma-cel* was infused for treatment in the first patient
2018
Jun
Relma-cel obtained first approval for clinical trial of CAR-T product targeting CD19 under IND pathway in China
2019
Apr
Successfully introduced BCMA-targeted cell therapy drug candidate (codename: JWCAR129)
Jun
Relma-cel was included in the National Significant New Drug Development Program
2020
Jun
Successfully submitted relma-cel’s NDA for its first indication LBCL
Sep
Relma-cel was granted priority review for its new drug application, and Breakthrough Therapy Designation
2021
Sep
Relma-cel was approved and launched in China
Sep
Received the IND approval for clinical trial of JWCAR129
2022
Feb
Successfully submitted sNDA for Carteyva® on FL
Mar
Received the IND clearance for clinical trial of Carteyva® on 2L LBCL
Apr
Received the IND clearance for clinical trial of Carteyva® on pALL
Jun
Initiated the clinical study of JWATM204 in advanced HCC, and infused the first patient for treatment

* Relmacabtagene autoleucel injection (relma-cel): JW Therapeutics’ lead product with trade name Carteyva®, and codename JWCAR029